Swedish-Based Cellcolabs is Making Stem Cell Therapies Mainstream

Cellcolabs, manufacturing High-Quality Mesenchymal Stromal Cells, led by Petter Hallman, Mattias Bernow, Lina Sörvik, Heidi Stensmyren, and others, has raised $12 million in a round led by Titian Capital.

Global demand for regenerative therapies is surging, yet high costs and limited production still restrict access for many patients. Stockholm-based Cellcolabs, founded in 2021 by Dr. Mattias Bernow, aims to change this through industrial-scale stem cell manufacturing. Its approach could reduce production costs by up to 90% over the next decade, making advanced cell therapies accessible worldwide.

Cellcolabs CEO Dr. Mattias Bernow said the industry is at an inflection point, with growing scientific validation and clearer regulatory pathways driving unprecedented demand for stem cells. However, he noted that scalable access remains the missing piece. The partnership with Titian Life Sciences, he added, provides both the capital and strategic reach needed for global expansion, laying the groundwork to make stem cell therapies widely accessible within our lifetime.

Inspired by breakthroughs at Sweden’s Karolinska Institutet, Cellcolabs aims to make high-quality stem cells accessible and affordable, bridging the gap between research and clinical application. Over two decades, the company has developed a proprietary GMP-certified process for producing mesenchymal stem cells (MSCs) at an industrial scale, meeting the highest standards for both research and therapeutic use. Unlike competitors such as Lonza Group, Thermo Fisher Scientific, and Stemcell Technologies, which rely on smaller, less standardized production models, Cellcolabs is building infrastructure designed for scalability and compliance, accelerating both regulatory progress and scientific discovery.

With the new funding, Cellcolabs will accelerate R&D, expand production capacity, and enter new international markets.